Johnson & Johnson posted third-quarter 2026 adjusted earnings per share of $2.59, surpassing the estimated $2.52. The company’s quarterly sales reached $25.40 billion, meeting market expectations for the period.
Segment performance showed a mix of results. Revenue from the medicine segment came in at $16.76 billion, exceeding the $16.59 billion estimate. In contrast, MedTech sales totaled $8.64 billion, falling short of the $8.77 billion forecast. Specific product lines contributed to these figures, with Darzalex generating $4.24 billion in revenue, below the $4.31 billion estimate, while Tremfya brought in $2.40 billion, beating the $2.21 billion projection.
For the full fiscal year, Johnson & Johnson projects sales between $101 billion and $101.4 billion. This range is slightly higher than the prior forecast, which had set the lower bound at $100.8 billion. The company now expects full-year adjusted earnings per share to land between $11.05 and $11.15, marking an increase from the earlier projection of $10.96 to $11.11. Adjusted operational earnings per share are projected at $10.95 to $11.05.
The company’s financial leadership also addressed corporate structure changes. The chief financial officer indicated that Johnson & Johnson is leaning toward a spinoff of its orthopaedic unit rather than pursuing an outright sale.